DPP4 and breast carcinoma: Some studies even found a reduced risk of breast cancer in diabetic patients treated with SGLT2i vs. DPP-4 inhibitors (HR: 0.51, p < 0.001) [65] or vs. non-SGLT2i users (HR: 0.77, p = 0.001) [66], and reduced breast cancer mortality in SGLT2i users vs. non-users [67].